Publications by authors named "Angela Wateska"

Claim this Profile
P
Public health effects of adult pneumococcal vaccination choice amid increased serotype 4 rates in US subpopulations.
Kenneth J Smith, Angela R Wateska, Mary Patricia Nowalk, Chyongchiou J Lin, Lee H Harrison

Public Health· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness and budget impact analyses of the 24-valent pneumococcal conjugate vaccine in adults aged 50 and older.
Shoroq M Altawalbeh, Angela R Wateska, Mary Patricia Nowalk, Chyongchiou J Lin, Lee H Harrison

Vaccine· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A budget impact analysis of 15- or 20- valent pneumococcal conjugate vaccine use in all US adults aged 50-64 years old compared to those with high-risk conditions from US payer perspective.
Nirma Khatri Vadlamudi, Chyongchiou J Lin, Angela R Wateska, Richard K Zimmerman, Kenneth J Smith

BMC Public Health· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-Effectiveness and Public Health Impact of 24-Valent Pneumococcal Conjugate Vaccine Compared With the Recommended Pneumococcal Vaccines in Older Adults.
Kenneth J Smith, Angela R Wateska, Mary Patricia Nowalk, Chyongchiou J Lin, Lee H Harrison

Am J Prev Med· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness of recombinant influenza vaccine compared with standard dose influenza vaccine in adults 18-64 years of age.
Mary Patricia Nowalk, Kenneth J Smith, Jonathan M Raviotta, Angela Wateska, Richard K Zimmerman

Vaccine· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Corrigendum to "Cost-effectiveness of an in-development adult-formulated 21-valent pneumococcal conjugate vaccine in US adults aged 50 years or older" [Vaccine 42 (2024) 3024-3032].
Shoroq M Altawalbeh, Angela R Wateska, Mary Patricia Nowalk, Chyongchiou J Lin, Lee H Harrison

Vaccine· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Changes in the cost-effectiveness of pneumococcal vaccination and of programs to increase its uptake in U.S. older adults.
Angela R Wateska, Mary Patricia Nowalk, Shoroq M Altawalbeh, Chyongchiou J Lin, Lee H Harrison

J Am Geriatr Soc· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pneumococcal Vaccination Strategies in 50-Year-Olds to Decrease Racial Disparities: A US Societal Perspective Cost-Effectiveness Analysis.
Shoroq M Altawalbeh, Angela R Wateska, Mary Patricia Nowalk, Chyongchiou J Lin, Lee H Harrison

Value Health· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness of an in-development adult-formulated 21-valent pneumococcal conjugate vaccine in US adults aged 50 years or older.
Shoroq M Altawalbeh, Angela R Wateska, Mary Patricia Nowalk, Chyongchiou J Lin, Lee H Harrison

Vaccine· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Societal Cost of Racial Pneumococcal Disease Disparities in US Adults Aged 50 Years or Older.
Shoroq M Altawalbeh, Angela R Wateska, Mary Patricia Nowalk, Chyongchiou J Lin, Lee H Harrison

Appl Health Econ Health Policy· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness of an in-development adult-formulated pneumococcal vaccine in older US adults.
Angela R Wateska, Mary Patricia Nowalk, Chyongchiou J Lin, Lee H Harrison, William Schaffner

Vaccine· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness of revised US pneumococcal vaccination recommendations in underserved minority adults < 65-years-old.
Angela R Wateska, Mary Patricia Nowalk, Chyongchiou J Lin, Lee H Harrison, William Schaffner

Vaccine· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-Effectiveness of Newly Recommended Pneumococcal Vaccination Strategies in Older Underserved Minority Adults in the USA.
Kenneth J Smith, Angela R Wateska, Mary Patricia Nowalk, Chyongchiou J Lin, Lee H Harrison

Infect Dis Ther· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Higher-Valency Pneumococcal Conjugate Vaccines: An Exploratory Cost-Effectiveness Analysis in U.S. Seniors.
Kenneth J Smith, Angela R Wateska, Mary Patricia Nowalk, Chyongchiou J Lin, Lee H Harrison

Am J Prev Med· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Should older adult pneumococcal vaccination recommendations change due to decreased vaccination in children during the pandemic? A cost-effectiveness analysis.
Kenneth J Smith, Angela R Wateska, Mary Patricia Nowalk, Chyongchiou J Lin, Lee H Harrison

Vaccine· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Is further research on adult pneumococcal vaccine uptake improvement programs worthwhile? Α value of information analysis.
Angela R Wateska, Mary Patricia Nowalk, Hawre Jalal, Chyongchiou J Lin, Lee H Harrison

Vaccine· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-Effectiveness of Pneumococcal Vaccination Policies and Uptake Programs in US Older Populations.
Angela R Wateska, Mary Patricia Nowalk, Chyongchiou J Lin, Lee H Harrison, William Schaffner

J Am Geriatr Soc· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pneumococcal Vaccination in Adults Aged ≥65 Years: Cost-Effectiveness and Health Impact in U.S. Populations.
Angela R Wateska, Mary Patricia Nowalk, Chyongchiou J Lin, Lee H Harrison, William Schaffner

Am J Prev Med· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An intervention to improve pneumococcal vaccination uptake in high risk 50-64 year olds vs. expanded age-based recommendations: an exploratory cost-effectiveness analysis.
Angela R Wateska, Mary Patricia Nowalk, Chyongchiou J Lin, Lee H Harrison, William Schaffner

Hum Vaccin Immunother· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-Effectiveness of Pneumococcal Vaccination and Uptake Improvement Programs in Underserved and General Population Adults Aged < 65 Years.
Angela R Wateska, Mary Patricia Nowalk, Chyongchiou J Lin, Lee H Harrison, William Schaffner

J Community Health· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Racial Disparities in Adult Pneumococcal Vaccination Indications and Pneumococcal Hospitalizations in the U.S.
Mary Patricia Nowalk, Angela R Wateska, Chyongchiou Jeng Lin, William Schaffner, Lee H Harrison

J Natl Med Assoc· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Compressed Influenza Vaccination in U.S. Older Adults: A Decision Analysis.
Kenneth J Smith, Glenson France, Mary Patricia Nowalk, Jonathan M Raviotta, Jay DePasse, Angela Wateska

Am J Prev Med· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness of adult pneumococcal vaccination policies in underserved minorities aged 50-64 years compared to the US general population.
Angela R Wateska, Mary Patricia Nowalk, Chyongchiou J Lin, Lee H Harrison, William Schaffner

Vaccine· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Potential Cost-Effectiveness of a Universal Influenza Vaccine in Older Adults.
Glenson France, Angela R Wateska, Mary Patricia Nowalk, Jay DePasse, Jonathan M Raviotta

Innov Aging· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness of increasing vaccination in high-risk adults aged 18-64 Years: a model-based decision analysis.
Angela R Wateska, Mary Patricia Nowalk, Richard K Zimmerman, Kenneth J Smith, Chyongchiou J Lin

BMC Infect Dis· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis